Abstract

A recent systematic evaluation found that on-site medication registrations and quality inspections may reduce counterfeit and substandard drugs. Replicating successful therapy without making any changes is tough. A complete data analysis was also the aim, in addition to systematic actions to combat medicine counterfeiting. We searched fourteen databases electronically throughout our extensive examination. We analysed data on the treatments' effectiveness, viability, reliability, financial results, and difficulties and prospects. After choosing relevant papers, two reviewers abstracted the data individually and in duplicate. A narrative synthesis was done on the findings, which were classified by intervention. The outcome Nineteen of 10,220 citations were acceptable. The results include reducing pharmaceutical diversion, improving communication, providing drug quality feedback, and lobbying for strict licencing regulations to strengthen regulatory systems like registration. Onsite quality monitoring and inspection solutions may be practical and cost-effective for large drug samples undergoing preliminary testing. Implement counterfeit pharmaceutical laws, strict fines, tools to control internet medication sales, and legal and judicial education. Public awareness and education initiatives need several platforms and specialist material. Product authentication systems can detect counterfeit medications in the supply chain, but they require a sound information system design to work. To ensure pharmacovigilance systems work, underreporting must be addressed. The following paragraphs will explore the aspects that affect the design and execution of systemic medication counterfeiting prevention methods. These must be considered by policymakers to ensure their efforts are effective.